Go Pro
LON:FUM

Futura Medical (FUM) Share Price, News & Analysis

Futura Medical logo
GBX 0.37 -0.08 (-17.78%)
As of 10:43 AM Eastern

About Futura Medical Stock (LON:FUM)

Advanced

Key Stats

Today's Range
0.37
0.50
50-Day Range
0.34
0.64
52-Week Range
0.24
10.50
Volume
7.27 million shs
Average Volume
9.35 million shs
Market Capitalization
£2.15 million
P/E Ratio
N/A
Dividend Yield
4.55%
Price Target
N/A
Consensus Rating
N/A

Company Overview

Futura Medical plc (AIM: FUM) is the developer of innovative sexual health products, including lead product Eroxon® and products WSD4000 and Eroxon® Intense. Our core strength lies in our research, development and commercialisation of topically delivered gel formulations in sexual health products. Sexual health issues are prevalent in both men and women. ED impacts 1 in 5 men globally across all adult age brackets, with approximately half of all men over 40 experiencing ED and 25% of all new diagnoses being in men under 40. Around 60% of women experience at least one symptom of sexual dysfunction, and only one in four women seek professional help, and remain chronically underserved. Eroxon®, Futura's clinically proven lead product, has been developed for the treatment of Erectile Dysfunction ("ED"). The highly differentiated product, which is the only topical gel treatment for ED available over the counter and helps men get an erection in ten minutes, addresses significant unmet needs in the ED market. Eroxon® has been nominated for a number of healthcare industry awards and has won two to-date. Futura has distribution partners in place in a number of major consumer markets including Haleon in the US, the largest market for ED in the world, and Cooper Consumer Health in Europe. WSD4000 is a topical treatment designed for the symptoms of impaired sexual response and function in women. There is currently no regulatory approved OTC treatment available for impaired sexual response and function in women. WSD4000 has the potential to be an effective, breakthrough treatment for the common symptoms associated with impaired sexual response and function, such as lack of desire, arousal and lubrication.

Receive FUM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Futura Medical and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

FUM Stock News Headlines

AIM Market Roundup: Focus Xplore, Futura Medical, Bravura Solutions
Your $29.97 book is free today
Why Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options can give you up to 12 times the leverage of stocks — with a fraction of the capital tied up. This free guide lays it all out in plain English — from A to Z, with step-by-step examples you can follow in your own account.tc pixel
Futura to appeal European patent decision
See More Headlines

FUM Stock Analysis - Frequently Asked Questions

Futura Medical's stock was trading at GBX 1.12 at the start of the year. Since then, FUM shares have decreased by 61.6% and is now trading at GBX 0.43.

Futura Medical plc (LON:FUM) announced its earnings results on Wednesday, April, 29th. The company reported ($2.78) earnings per share for the quarter. The company earned $1.70 million during the quarter. Futura Medical had a negative net margin of 534.62% and a negative trailing twelve-month return on equity of 310.00%.

Shares of FUM stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

Based on aggregate information from My MarketBeat watchlists, some other companies that Futura Medical investors own include Indivior (INDV), Tullow Oil (TLW), Lloyds Banking Group (LLOY), Bigblu Broadband (BBB), BP (BP), Directa Plus (DCTA) and Genel Energy (GENL).

Company Calendar

Last Earnings
4/29/2026
Today
8/14/2026

Industry, Sector and Symbol

Stock Exchange
LON
Industry
Biotechnology
Sub-Industry
Biotechnology
Current Symbol
LON:FUM
CIK
N/A
Fax
N/A
Employees
12
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
GBX (2.78)
Trailing P/E Ratio
N/A
Forward P/E Ratio
0.15
P/E Growth
N/A
Net Income
-£3.88 million
Net Margins
-534.62%
Pretax Margin
N/A
Return on Equity
-310.00%
Return on Assets
-26.59%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
2.06
Quick Ratio
5.73

Sales & Book Value

Annual Sales
£1.70 million
Price / Sales
1.47
Cash Flow
GBX 0.02 per share
Price / Cash Flow
20.43
Book Value
GBX 2.59 per share
Price / Book
0.17

Miscellaneous

Outstanding Shares
581,328,000
Free Float
N/A
Market Cap
£2.50 million
Optionable
Not Optionable
Beta
0.02
Options Trading Made Easy - Download Now Cover

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

This page (LON:FUM) was last updated on 8/14/2026 by MarketBeat.com Staff.
From Our Partners